The Sept. 16-18 event will feature key research and investing opportunities and the growing role of women in bioscience careers, as well as presentations by renowned innovators about emerging translational therapies in the bench-to-the-bedside continuum

(Portland, Ore.) — ‘The Economics of Life Sciences’ will be the theme of Oregon Bioscience Association’s 2013 annual conference which launches on Monday, September 16 and continues through Wednesday, Sept. 18. Keynoter and featured speakers include nationally renowned thought leaders in the innovation economy, product and therapeutic development, industry funding, scientific breakthrough research and health reform such as:
· William Brody, M.D., president of The Salk Institute for Biological Studies
· Michael Crowley, Ph.D., director of business development, Genentech
· Colin Hill, CEO and founder, GNS Healthcare
· Rob Coppedge, senior vice president, Strategic Investments at Cambia Health Solutions
· Joel V. Brill, M.D., gastroenterologist and reimbursement expert
· David Sanders, M.D., founder, Zoomcare Inc.
· Elena Taggart Medo, chairman and CEO, Neolac

“We are anticipating another year of sellout crowds, as each year this conference attracts the broadest cross-section of regional, national and international investors and strategic partners who are interested in learning more about the opportunities available in Oregon,” said Oregon Bioscience Association’s Executive Director, Dennis McNannay.  “The format of this event allows attendees the opportunity to meet one-on-one with prospective investment partnering companies and to learn about the deep pool of research expertise Oregon can offer through its bioscience-based signature research institute, OTRADI, other signature research centers, and university-based programs.”

Day One on Sept. 17 will focus on bio-partnering and investing.  Attendees will learn about emerging strategies in product design, supply chain management, reimbursement, resolving investor barriers, courting new customers, outsourcing for profitability and modeling the new world of health care reform. Also, the conference will again feature the well known Oregon Research Pavilion, sponsored by OTRADI (Oregon Translational Research and Development Institute) and ONAMI (Oregon Nanoscience and Microtechnologies Institute). Aimed at attracting potential partners and investors, the pavilion will showcase  Oregon’s top research initiatives. Each featured academic research poster and emerging company presenter was selected based on commercialization or investment potential. This year all researchers will provide a three-minute thesis video opportunity profiling their work.

Day two on Sept. 18 will focus on how the shifting economic winds are changing the bioscience industry. Notes McNannay, “From a tighter reimbursement environment to breakthroughs in how bioscience products are funded and developed, I think we all agree it’s time to embrace change.” The second day will detail how experts might advise attendees how to compete in the new age; how to achieve bioscience ROI in efficiency, quality, price and value; how to accelerate company formation; find international opportunities; advance in mobile healthcare markets; and advocate for bioscience and access-friendly policies. The new Oregon Bio Women special interest group will feature its first ever pre-conference workshop during the afternoon of Sept. 16. Opening speakers and hosted interactive roundtables on leadership and social media topics will be featured.
Oregon Bio thanks its conference Platinum sponsors OTRADI and ONAMI; Silver sponsors Galena Biopharma, HDR Architecture, Inc., Medmarc, MolecularMD, Sheldon Manufacturing and Eli Lilly; and Track sponsors Biotechnology Industry Organization, Biotronik/Micro Systems Engineering, Genentech and Welch Allyn.

Registration is now open for the Sept. 16-18. The early bird registration deadline ends Aug. 30. Click on https://s08.123signup.com/servlet/SignUp?P=15363021911426713700&PG=1536302182300 to register or call the association at (503) 548-4432